Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German Pharma Industry Cries Foul As Preliminary Evaluation Of AMNOG Suggests It Works

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany’s powerful health care watchdog G-BA, in its first full opinion on early added benefit assessment of medicines, says the process is fair and promotes real drug innovation, in sharp contrast to the biopharma industry which maintains it is a cost-cutting tool wielded by health insurance funds.

Advertisement

Related Content

German Drug Report Could Mean More Pressure On Pharma Revenues
German HTA Blueprint Could Be Imposed On Greece
Germany’s IQWiG: New Year, Same Sternness On Dossier Structure
German Pricing Plan Avoids Terrible Twos, But More Growing Pains Ahead
German Authorities Stonewall Pharma’s Transparency Demands
AstraZeneca Blames Germany’s Tender System For Influenza Vaccine Shortages
German Joy For Pharma As Drug Discount Prices Stay Hidden
Germany’s IQWiG Downs Two Drugs In One Day
Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta
New German Reimbursement Process Splits Opinion Ahead Of First Assessments

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074717

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel